ABD-350 is ligand-induced inhibitor of nuclear factor kappaB phosphorylation. It causes osteoclast apoptosis without effects of biphosphonates such as bone formation inhibition and anabolism of PTH. ABD-350 has potent antiresorptive effects in vitro and in vivo that do not adversely affect osteoblast function. ABD350 prevented ovariectomy-induced bone loss. References: Idris AI, Greig IR, Bassonga-Landao E, Ralston SH, van 't Hof RJ. Identification of novel biphenyl carboxylic acid derivatives as novel antiresorptive agents that do not impair parathyroid hormone-induced bone formation. Endocrinology. 2009 Jan;150(1):5-13. doi: 10.1210/en.2008-0998. Epub 2008 Sep 4. PubMed PMID: 18772231.

纯度：≥98%

CAS：1117772-52-7